266 filings
8-K
BPTH
Bio-Path Holdings Inc
19 Apr 24
Other Events
3:31pm
8-K
BPTH
Bio-Path Holdings Inc
19 Apr 24
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the- Market Under Nasdaq Rules
9:21am
8-K
BPTH
Bio-Path Holdings Inc
18 Apr 24
Other Events
9:13am
8-K
BPTH
Bio-Path Holdings Inc
15 Apr 24
Bio-Path Holdings Expands Global Patent Portfolio
7:30am
8-K
BPTH
Bio-Path Holdings Inc
4 Apr 24
Entry into a Material Definitive Agreement
4:35pm
8-K
j2c 1ollm5u
2 Apr 24
Bio-Path Holdings Provides 2024 Clinical and Operational Update
4:10pm
8-K
33gnsl39mek13z df4
27 Mar 24
Other Events
8:20am
8-K
2b5 qra4scj2iglxy8nk
26 Mar 24
Entry into a Material Definitive Agreement
8:03am
8-K
9b3vc2puqq8
13 Mar 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
iaaq3n
11 Mar 24
Other Events
7:00am
8-K
ggwgja99zpgv 6r57y4
8 Mar 24
Bio-path Holdings Reports Full Year 2023 Financial Results
7:10am
8-K
hkmr4o4a19e2w 6by3h
23 Feb 24
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
7:01am
8-K
bijpxcgws 62io43q40
2 Feb 24
Submission of Matters to a Vote of Security Holders
4:10pm
8-K
mdqcdxoml
23 Jan 24
Submission of Matters to a Vote of Security Holders
5:20pm
8-K
3oxn31hjkiusdd7 sd
10 Jan 24
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy
4:10pm
8-K
yb2 yi1ms87rx4on6dd
15 Dec 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
vw94o0rcf06br67q7
14 Dec 23
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
4:05pm
8-K
2r1byv3
8 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
3mztgnmi gr
15 Nov 23
Bio-path Holdings Reports Third Quarter 2023 Financial Results
7:30am
8-K
k6dqw
24 Oct 23
Regulation FD Disclosure
4:30pm